🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06044129
Starting soon Observational

A Novel Approach Integrating Magnetic Resonance Imaging (MRI) Data and Artificial Intelligence for Predicting the Success Rate of Vaginal Delivery in Pregnant Women

NCT06044129 · tracked via the Priya Life Science China tracker
Sponsor
Second Affiliated Hospital of Wenzhou Medical University
Phase
Observational
Started
2024-01-01
Last updated
2023-09-21

Condition(s) studied

Vaginal Delivery

Investigational drug(s) / intervention(s)

Mri scan of fetal head and pelvis

Mri scan of fetal head and pelvis: The pelvic parameters and fetal head parameters of pregnant women were measured by MRI, including pelvic entrance plane, middle pelvic plane, pelvic outlet plane, pubic arch Angle, double parietal diameter, occipitofrontal diameter, and suboccipital fontanel diameter.

Study summary

The aim of this study was to use MRI imaging to accurately scan the pregnant woman's pelvis and fetal skull, build a 3D model of them, and combine with artificial intelligence to develop an accurate tool to predict the success rate of vaginal delivery.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
35 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Full-term. * Single fetus, head first. * Pregnant women have vaginal couvade wishes. * Complete clinical data of pregnant women. Exclusion Criteria: * Pregnancy with serious medical and surgical diseases. * Abnormal fetal position (such as transverse, breech, etc.). * Twin or multiple pregnancies. * Vaginal couvade contraindications such as placenta previa.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
department of obstetrics of Second Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang

More Second Affiliated Hospital of Wenzhou Medical University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06044129 on ClinicalTrials.gov ↗ ← All trials in China